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Abstract
Mitotane is the reference drug for adrenocortical carcinoma (ACC) and the metabolic activa-
tion of the drug is considered as essential for its activity. The aim of this study was to assess
the role of CYP11B1 on mitotane action and metabolism in H295R ACC cells to understand
whether this enzyme may influence mitotane action. The simultaneous incubation with mito-
tane and metyrapone, an adrenolytic molecule targeting 11-beta-hydroxylase, did not influ-
ence mitotane-mediated cytotoxic effect and metabolism in H295R ACC cells. CYP11B1
silencing confirmed the lack of a significant metyrapone effect on mitotane action. The pres-
ent findings do not support the view that CYP11B1 catalyzes a crucial step in the metabolic
activation of mitotane and that CYP11B1 confers the adrenal specificity to mitotane.
Introduction
Adrenocortical carcinoma (ACC) is a rare and malignant endocrine tumor with a generally
poor prognosis [1, 2]. Mitotane (o,p’DDD), a metabolite of the insecticide dichlorodiphenyltri-
chloroethane (DDT), is the reference treatment for ACC, and is used either in the post-opera-
tive adjuvant setting following ACC extirpation or for treatment of advanced ACC [3, 4].
Mitotane acts on the adrenal glands inhibiting cell growth and impairing steroidogenesis [5].
Critical steps of the inhibitory effects on steroidogenesis may occur in mitochondria possibly
involving CYP11A1, a mitochondrial enzyme that catalyzes the transformation of cholesterol
to pregnenolone [6]. Elevated levels of 11-deoxycortisol and 11-deoxycorticosterone in mito-
tane-treated patients suggest that mitotane may affect CYP11B1 [7].
Metabolic activation of mitotane is considered to be essential for the therapeutic effect,
through transformation into two metabolites, 1,1-(o,p’-dichlorodiphenyl)-2,2 dichloroethene
(o,p’-DDE) and 1,1-(o,p’-dichlorodiphenyl) acetic acid (o,p’-DDA) by α- and β-hydroxylation,
respectively [8]. Mitotane is metabolized through a reactive acyl chloride thought to bind adre-
nal cortical bionucleophiles as well as to serve as the intermediate in the formation of o,p’-
DDA, probably by means of a cytochrome P450 (CYP) enzyme [9, 10]. The metabolic activa-
tion of mitotane may take place in the tumor and be dependent on either CYP11B1 or a non-
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steroidogenic CYP, and there is some evidence that the capability of the tumor to metabolize
mitotane may predict response to treatment [11, 12]. Although there is no straight evidence
that CYP11B1 is the key CYP enzyme in this process, there are in vitro and ex vivo data pro-
viding indirect support to the view that CYP11B1 activates mitotane [13, 14]. Transfection of
the CYP11B1 gene into monkey COS cells was able to induce uptake and metabolization of a
mitotane analog, MeSO2-DDE [15]. It should be taken into account, however, the different
molecular structure of MeSO2-DDE compared to mitotane. Overall, the literature on this
topic remains controversial [16]. It may seem paradoxical that the activity of mitotane may
derive from metabolic transformation via an enzyme system that is inhibited by mitotane itself.
However, the effect of mitotane on CYP11B1 mRNA expression was recently reported to be
biphasic, being more stimulatory than inhibitory over a wide concentration range of the drug
[17].
Metyrapone has been in use since the 1960s for the medical management of Cushing’s syn-
drome [18]. Metyrapone has been used alone or in combination with other agents including
mitotane [19], and explicates its action by inhibiting adrenal beta-hydroxylation of 11-deoxy-
cortisol, the final step in cortisol synthesis. The block of this enzymatic reaction results in a
reduction of adrenal cortisol production [20]. Metyrapone did not show any significant inter-
ference on o,p0-DDD binding in murine adrenocortical Y-1 cells [21] but partially reduced o,
p0-DDD binding in human adrenal tissue-slice culture [14].
Despite that mitotane has been largely used to treat ACC patients, we still do not know pre-
cisely the mechanisms of action of this old drug. The aim of this study was to assess the role of
CYP11B1 on mitotane action and metabolism in an ACC cell line to understand whether this
enzyme may influence mitotane action.
Materials and methods
Cell culture and chemical reagents
H295R ACC cell line (ATCC CRL-2128) was supplied from the American Type Culture Col-
lection (ATCC, Rockville, MD, USA). The H295R cells were cultured in a 1:1 mixture of Dul-
becco’s Modified Eagle’s Medium and Ham’s F-12 Nutrient mixture (DMEM/F12) (Sigma-
Aldrich, Saint Louis, United States, Saint Louis, United States) supplemented with 2 mmol/L
L-glutamine, penicillin (25 units/mL), and streptomycin (25 mg/mL, all from Sigma-Aldrich,
Saint Louis, United States) and 2.5% of Nu-Serum (Corning, NY,USA) and enriched with 1%
di ITS+Premix (Corning, NY,USA). Mitotane (purity >99.9%, Cat. Numb. 49015, Supelco,
Bellefonte, United States) was dissolved in 100% methanol (Sigma-Aldrich, Saint Louis,
United States) and metyrapone (Sigma-Aldrich, Saint Louis, United States) was dissolved in
DMSO.
Treatment and cell viability assay
H295R cells were seeded into 96-well plates in triplicates and treated with mitotane (from 5 to
50 μM) and metyrapone (20 μM) used alone or in association for 48h. Mitotane concentrations
are in a range comparable to that associated with therapeutic effect in vivo [9]. Metyrapone
concentration is close to the peak concentration of 16.3 μM observed in plasma after 1h follow-
ing administration of 750 mg of the drug [22]. After incubation time, Cell Proliferation
Reagent WST-1 (Roche Applied Science, Penzberg, Germany) was added to each well in order
to measure cell viability, following the supplied protocol. The absorbance was determined
using a microplate reader (iMARK microplate reader) (Biorad Life Science Group, Hercules,
CA USA) at a test wavelength of 450 nm and reference wavelength of 630 nm.
CYP11B1 and mitotane in adrenocortical carcinoma cells
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Measurement of mitotane and its metabolites
Mitotane (o,p’-DDD), o,p’-DDE and o,p’-DDA concentrations were evaluated using a HPLC
system (High Pressure Liquid Chromatography, VWR-Hitachi system, LaChrom Elite) after
previous specific extraction [23]. These compounds were extracted from equal amounts of cell
lysates and surnatants after mitotane treatment (25 μM) for 48h alone or with metyrapone
(20 μM) and after CYP11B1 siRna inhibition. Extraction of mitotane, o,p’-DDE and p,p’-
DDT, used as internal standard (IS), was performed by vortex mixing of 500 μl of samples with
100 μl of IS (100mg/ml) and 750 μl of acetone. Samples were then centrifuged at 12000 rpm
for 5 min and 500 μl of organic layer were transferred to a HPLC vial mixed with 500 μl of
recovering phase (HPLC-grade water-methanol-acetonitrile, 40:10:50, v/v/v) for injection.
Separation was then achieved with a C18 reverse-phase column (LiChroCART1 250–4 HPLC
Cartridge, LiChrospher1 100, RP-18, 5 mm, VWR) preceded by a specific guard column.
Chromatographic analysis was carried out at 30˚C by a gradient of HPLC-grade water, metha-
nol, acetonitrile (0–6.5 min 10:10:80, v/v/v; 6.6–9.7 min 5:5:90, v/v/v; 9.7–15 min 10:10:80, v/v/
v) at the constant flow rate of 1.0 ml/min. The eluate was scanned at 218 nm.
A different method was adopted for o,p’-DDA to eliminate interferences at the compound
retention time. Extraction of o,p’-DDA and nilotinib, used as IS, was performed by protein
precipitation: 50 μl of IS working solution (200mg/ml) were added to 500 μl of samples. After
750 μl of protein precipitation solution (HPLC-grade water and methanol, 50:50, v/v) were
added to each sample, tubes were vortexed for 30 sec and then centrifuged at 12000 rpm for 10
min. Finally 800 μl of organic layer were transferred to a HPLC vial for injection. Separation
was then achieved with a C18 reverse-phase column (LiChroCART1 250–4 HPLC Cartridge,
LiChrospher1 100, RP-18, 5 mm, VWR) preceded by a specific guard column. Chro-
matographic analysis was carried out under isocratic elution at 35˚C by a mobile phase consist-
ing of 40% solvent A (72.5% water, 25% methanol, 2.5% triethylamine), 20% methanol, and
40% acetonitrile at the constant flow rate of 0.9 ml/min. The eluate was scanned at 267 nm.
System management and data acquisition were performed with the EzChrom Elite software.
Quantification was performed by IS calibration; a linear regression was used in order to obtain
the best fit for all calibration points. Regression coefficient (r2) of all calibration curves was
higher than 0.99 for all compounds.
Measurement of cortisol
Cortisol was measured from equal amounts of surnatant after mitotane treatment for 48h
alone or with metyrapone and after CYP11B1 siRna inhibition. Cortisol levels were measured
on surnatants and were normalized by the number of cells harvested in order to take into
account the toxic effects of mitotane. Cortisol was measured by commercially available radio-
immunoassay kits (Beckman Coulter, Fullerton, CA, United States). Dynamic ranges and
detection limits were as follows: cortisol: 7.2–724 μg/L. Intra- and inter-assay coefficients of
variation values were<5%.
Evaluation of CYP11B1 expression
H295R cells were cultured into six-well plates and treated with mitotane for 48 h. Total RNA
was extracted using Qiazol Reagent (Qiagen, Hilden, Germany). Complementary DNA was
generated using M-MLVT RT (200U/μl) (Invitrogen, Carlsbad, United States) and oligodT
primers (500μl/ml) (Invitrogen, Carlsbad, United States) from 1μg of total RNA. Relative
cDNA quantification for CYP11B1 and a housekeeping gene (beta-actin) were examined by
quantitative real-time (RT)-PCR using a validated assay probe (RealTime ready Catalog
Assays, Roche Applied Science, Penzberg, Germany). To analyze target gene expression in
CYP11B1 and mitotane in adrenocortical carcinoma cells
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treated cells, levels of CYP11B1 mRNA were normalized to housekeeping gene beta-actin,
then ΔΔCt calculation was performed and corresponding values were expressed as 2-ΔΔCt.
Silencing experiments
For CYP11B1 silencing experiments, pre-designed iBoni siRna Pool targeting CYP11B1 and
pre-designed iBoni siRna Pool negative control were used (RIboxx, Radebeul, Germany).
INTERFERin siRna transfection reagent was purchased from Polyplus transfection (Illkirch,
France). Briefly, using a reverse transfection, siRnas (at a final concentration of 50 nmol/L)
and INTERFERin were diluted in medium without serum and incubated for 10 minutes at
room temperature. Lipoplexes were then transferred to multi-well tissue culture plates and
overlaid with H295R ACC cells. After 24 hours, the medium was changed, and the cells were
then cultured in medium alone (basal) or in medium containing mitotane (from 5 to 50 μM
for cell viability, 25μM for HPLC analysis). Assessment of cell viability, measurement of corti-
sol, mitotane and its metabolites were done as described above.
Statistical analysis
Statistical analyses were done by means of the Student’s t-test. All p values reported are the
result of two-sided tests. Data are presented as mean ± standard error (SE). Level of statistical
significance is<0.05.
Results
Effects of metyrapone and mitotane on cortisol production
In H295R cells, cortisol levels were significantly reduced after a 48h treatment with metyra-
pone (20 μM) and mitotane (25 μM), used either alone or in association. Cortisol levels in
untreated cells of 25.2 ± 4.3 μg/L were reduced by metyrapone treatment to 18.9 ± 0.3 μg/L
(p = 0.03) and by mitotane to 19.8 μg/L ± 0.7 μg/L (p = 0.049). After combined treatment
with mitotane plus metyrapone, cortisol levels were 15.6 ± 0.8 μg/L (p = 0.005) (Fig 1) (S1
Table).
Fig 1. Effects of 25 μM mitotane and 20 μM metyrapone on cortisol levels. Four independent experiments were used to
determine each data point. Metyrapone or mitotane treatment vs. untreated cells, P<0.05. Combined treatment with mitotane
and metyrapone vs. untreated cells. P = 0.005.
https://doi.org/10.1371/journal.pone.0196931.g001
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Effects of metyrapone on mitotane activity
Mitotane treatment induced a cytotoxic effect in H295R ACC cell line. The combination of
mitotane and metyrapone showed a similar effect on cell viability in comparison to mitotane
alone (Fig 2). Metyrapone did not show any effect on cell viability -cell viability ratio for
untreated control, 99.8 ± 0.33 vs 20μM metyrapone, 100.01 ± 0.25, (p = ns) (S2 Table). Levels
of mitotane, o,p’DDE and o,p’DDA were measured in cellular pellets and in surnatants. Their
levels in both intracellular and extracellular compartments of H295R cells were not influenced
by concomitant treatment with metyrapone (p = ns) (Fig 3) (S3 Table).
Effects of mitotane on CYP11B1 gene expression
Mitotane treatment induced a strong down-regulation of CYP11B1 gene expression in H295R
ACC cell line (< 0.5 fold change compared to untreated cells), while metyrapone induced a
non-significant increase (< 2 fold increase compared to untreated cells). Cotreatment with
mitotane and metyrapone induced an even greater down-regulation of CYP11B1 gene expres-
sion (Fig 4).
Effects of CYP11B1 inhibition on mitotane activity and metabolization
To investigate the possible role of CYP11B1 on mitotane activity and metabolism we modu-
lated CYP11B1 expression by RNA specific silencing in H295R cells. Efficiency of transfection
was measured by means of flow cytometry showing a 7-fold increase in fluorescent signal in
comparison to untransfected control cells (Fig 5A). CYP11B1 mRNA expression in H295R
cells was knocked down by CYP11B1 siRna to less than 20% of control cells transfected with
non-targeting siRna (Fig 5B). Moreover, knockdown of CYP11B1 was further demonstrated
by the reduction of cortisol concentration—cortisol levels for CYP11B1 siRna cells 13. μg/
L ± 0.8 vs. non-targeting siRna cells 9.8 μg/L ± 1.3, p = 0.005 - (Fig 5C) (S4 Table). Silencing
CYP11B1 gene in H295R cells did not determinate any change in the effects of mitotane on
Fig 2. Effects of mitotane and 20 μM metyrapone on H295R cell viability. Three technical replicate wells for each experiment (n = 3) were used
to determine each data point. P = ns comparing mitotane treatment vs. combined treatment with mitotane and metyrapone.
https://doi.org/10.1371/journal.pone.0196931.g002
CYP11B1 and mitotane in adrenocortical carcinoma cells
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cell viability (Fig 6A) and did not influence mitotane uptake, bioavailability and metabolism
into o,p’DDE and o,p’DDA (p = ns) (Fig 6B) (S5 Table).
Discussion
Mitotane is the reference drug for advanced ACC and clinicians exploit either its cytotoxic
effect or the inhibition of different steroidogenic enzymes [1–4, 12]. Mitotane was introduced
in clinical use to treat advanced ACC in the sixties [2] but its mechanism of action remains
poorly understood. The concept that a metabolic transformation of mitotane is needed for its
therapeutic activity is supported by the observation of a huge inter-species variation of the
adrenolytic effects of the drug that parallels the different adrenal capability to transform mito-
tane [11, 12, 16]. It has been suggested that the metabolic transformation of mitotane takes
place in the adrenal mitochondria and that CYP11B1 may be involved in the initial
Fig 3. Mitotane metabolites in ACC cells: Uptake, bioavailability and metabolization. Intracellular and extracellular
concentration of mitotane and its metabolites in H295R, measured by means of HPLC–UV after metyrapone treatment. Six
independent experiments were used to determinate each data point.
https://doi.org/10.1371/journal.pone.0196931.g003
Fig 4. CYP11B1 expression after treatment with mitotane and metyrapone, or both. Data obtained from two independent
experiments with two replicates for each experiment, and expressed as fold changes compared to β-actin expression (2-ΔΔCt).
A> 2 fold increase was considered significant.
https://doi.org/10.1371/journal.pone.0196931.g004
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hydroxylation of mitotane [6, 13–15, 14]. The fact that CYP11B1 is required to activate mito-
tane may confer tissue specificity to mitotane, thus explaining why mitotane does not affect
SW13 cells [24], which do not express CYP11B1 [25]. However, the concept that mitotane
metabolites are important to explicate an anti-tumoral action has been challenged by a recent
study, where o,p’-DDA was found to be inactive in H295R cells [26]. Downstream stable
metabolites could simply reflect the process of acyl chloride formation. The issue remains con-
troversial since in vitro research by our group found that mitotane metabolites (o,p’-DDE and
o,p’-DDA) had cytotoxic activity in H295R cells [27]. Moreover, there is also a study showing
that elevated o,p’-DDA levels in patients with advanced ACC were associated with better
patient outcome [9].
The present findings do not support the view that CYP11B1 catalyzes a crucial step in the
metabolic activation of mitotane, since the concomitant incubation of H295R cells with mito-
tane and metyrapone, a drug capable of inhibiting CYP11B1 [18], did not influence mitotane-
mediated cytotoxic effect. Furthermore, CYP11B1 silencing by specific siRna did not alter
mitotane action in our experimental model. Pertinently, changes in CYP11B1 activity or gene
expression were also without any major effect on mitotane transformation. In H295R cells,
Fig 5. Efficiency of siRna transfection and silencing. (A) H295R cells transfected with a fluorescent siRna indicator. (B) CYP11B1 gene expression in
CYP11B1 siRna cells and non-targeting siRna cells. Data obtained from two independent experiments with two replicates for each experiment. (C) Cortisol
levels in CYP11B1 siRna cells and non-targeting siRna control cells. Four independent experiments were used to determine each data point.
https://doi.org/10.1371/journal.pone.0196931.g005
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uptake and metabolism of mitotane into o,p’-DDE and o,p’-DDA was unchanged after metyr-
apone treatment or CYP11B1 silencing.
The concomitant incubation of H295R cells with mitotane and metyrapone resulted in a
larger effect on cortisol production. This is consistent with the view that CYP11B1 does not
represent a major target in the mitotane-induced inhibition of adrenal steroidogenesis [28],
although inhibition of CYP11B1 and 18-hydroxylation (CYP11B2) has been shown in slices of
adrenal glands taken from patients treated with mitotane [29]. More recent in vitro studies did
not solve the issue whether mitotane is able to consistently affect CYP11B1 [17]. However, the
present findings confirm the synergist effect of both drugs to control severe Cushing’s syn-
drome [19] and are reassuring physicians that the association of metyrapone does not impact
on the anti-tumoral efficacy of mitotane. This is clinically relevant since the management of
Cushing’s syndrome associated with ACC is often challenging and mitotane has the drawback
of a delayed onset of action [2, 12]; thus, the combination with a fast-acting drug like metyra-
pone may be useful to get a rapid control of severe cortisol excess [30].
Fig 6. Mitotane cytotoxicity and metabolism after CYP11B1 modulation in H295R cell line. (A) Mitotane cytotoxicity was not influenced by
CYP11B1 interference (p = ns, comparing IC50 doses of CYP11B1 siRna cells and non-targeting siRna control cells). Three replicate wells for each
experiment (n = 2) were used to determine each data point. (B) CYP11B1 modulation did not influence uptake of mitotane and its metabolization
(p = ns, comparing drug levels of CYP11B1 siRna cells and non-targeting siRna control cells). Four independent experiments were used to
determinate each data point, measured in HPLC-UV.
https://doi.org/10.1371/journal.pone.0196931.g006
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To conclude, we have shown that CYP11B1 modulation in H295R cells, by either chemical
or molecular inhibition, is not able to affect mitotane action. These data militates against the
view that CYP11B1 may play a key role in the metabolic activation of mitotane to ensure its
antineoplastic activity. Other mechanisms may explain why mitotane targets the adrenal
glands for its cytotoxic action. It has been recently demonstrated how mitotane may inhibit
the sterol-O-acyl-transferase 1 (SOAT1) that is predominantly expressed by the adrenals. The
inhibition of this enzyme results into an accumulation of free cholesterol at toxic levels for the
cell [31]. Conversely, the inhibition of steroidogenesis is not limited to the adrenal glands,
since mitotane is able to impair testicular production of testosterone in patients on chronic
treatment [32].
Supporting information
S1 Table. Cortisol levels after mitotane and 20 μM metyrapone treatment in H295R cells.
Levels are expressed in μg/L.
(TIF)
S2 Table. Cell viability ratio levels after mitotane and 20 μM metyrapone treatment in
H295R cells.
(TIF)
S3 Table. Mitotane and metabolites levels after mitotane and 20 μM metyrapone treatment
in H295R cells. Levels are expressed in mg/L.
(TIF)
S4 Table. Cortisol levels after CYP11B1 silencing in H295R cells. Levels are expressed in μg/
L.
(TIF)
S5 Table. Mitotane and metabolites levels after CYP11B1 silencing in H295R cells. Levels
are expressed in mg/L.
(TIF)
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